Karyopharm cancer trial selected for late-breaking presentation at EHA

June 2, 2026 10:03 AM

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) announced that its Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis was selected ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found